<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813523</url>
  </required_header>
  <id_info>
    <org_study_id>TianjinCIH20210169</org_study_id>
    <nct_id>NCT04813523</nct_id>
  </id_info>
  <brief_title>Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma</brief_title>
  <acronym>KEYSTONE-003</acronym>
  <official_title>Efficacy and Safety of Pembrolizumab Plus Neoadjuvant Chemotherapy With Cisplatin and 5-Fluorouracill Followed by Surgery in Patients With Locally Advanced Adenocarcinoma of Esophagogastric Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab&#xD;
      plus cisplatin and 5-fluorouracil (5-FU) followed Surgery for locally advanced adenocarcinoma&#xD;
      of esophagogastric junction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The neoadjuvant chemotherapy/chemoradiotherapy with surgery is the standard treatment in NCCN&#xD;
      guideline. But many patients refused or abandon radiotherapy because of the intolerable&#xD;
      adverse effects. We designed a single-arm, open-label, phase II trial of pembrolizumab plus&#xD;
      cisplatin and 5-fluorouracil (5-FU) followed by radical surgery for locally advanced&#xD;
      adenocarcinoma of esophagogastric junction. The purpose of this study is to observe and&#xD;
      evaluate the efficacy and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathologic response (MPR)</measure>
    <time_frame>one month after surgery</time_frame>
    <description>Viable tumor comprised ≤ 10% of resected tumor specimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from the enrollment to disease relapse after complete resection or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from the enrollment to death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response (pCR)</measure>
    <time_frame>one month after surgery</time_frame>
    <description>No tumor residue of resected tumor specimens</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Adenocarcinoma of Esophagogastric Junction</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <condition>Pembrolizumab</condition>
  <arm_group>
    <arm_group_label>Experimental: Pembrolizumab+Cisplatin+5-FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive preoperative pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 600 mg/m^2/day IV infusion on Days 1 to 5. There are 3 cycels of preoprative therapy and 3 cycles of postoperative therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Injection [Keytruda]</intervention_name>
    <description>Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.</description>
    <arm_group_label>Experimental: Pembrolizumab+Cisplatin+5-FU</arm_group_label>
    <other_name>Cisplatin</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed AEG, Siewert type I or II;&#xD;
&#xD;
          2. Potentially resectable cT3-4a, any N, M0 (AJCC 8 TNM classification);&#xD;
&#xD;
          3. Have a performance status of 0 or 1 on the ECOG Performance Scale;&#xD;
&#xD;
          4. Age 18-75 years old, both men and women;&#xD;
&#xD;
          5. Be willing and able to provide written informed consent/assent for the trial;&#xD;
&#xD;
          6. Demonstrate adequate organ function , all screening labs should be performed within 10&#xD;
             days of treatment initiation;&#xD;
&#xD;
          7. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required;&#xD;
&#xD;
          8. Be willing to provide tissue from a newly obtained core or excisional biopsy of a&#xD;
             tumor lesion through repeated biopsies. Newly-obtained is defined as a specimen&#xD;
             obtained up to 4 weeks (28 days) prior to initiation of treatment on Day 1. Subjects&#xD;
             for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject&#xD;
             safety concern) may submit an archived specimen only upon agreement from the Sponsor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for AEG;&#xD;
&#xD;
          2. Ineligibility or contraindication for esophagectomy;&#xD;
&#xD;
          3. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to the first dose of study drug;&#xD;
&#xD;
          4. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs);&#xD;
&#xD;
          5. Has severe hypersensitivity and adverse events (≥Grade 3) to nivolumab and/or any&#xD;
             PD-1/PD-L1 inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongjing Jiang, MD, PhD</last_name>
    <phone>8618622221069</phone>
    <email>jianghongjing@tmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaofeng Duan, MD, PhD</last_name>
    <phone>8613752437179</phone>
    <email>xduan@tmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongjing Jiang, MD,PhD</last_name>
      <phone>8618622221069</phone>
      <email>jianghongjing@tmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiaofeng Duan, MD,PhD</last_name>
      <phone>8613752437179</phone>
      <email>xduan@tmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

